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Abstract Paravalvular leak (PVL) is a serious complication
after surgical valve replacement or after transcatheter aortic
valve replacement. Approximately 1–5% of PVLs can lead
to serious clinical consequences, including congestive heart
failure and/or haemolytic anaemia. For years, surgical re-
intervention has been considered the treatment of choice
for symptomatic patients with PVLs. However, surgical re-
intervention is associated with a high risk of morbidity and
mortality. Transcatheter PVL (TPVL) closure is a less inva-
sive alternative to surgical re-intervention. The safety and
feasibility of TPVL closure has been confirmed in several
registries and a meta-analysis.
In this review, we discuss the clinical implications and
diagnosis of PVLs, technical considerations for TPVL, ex-
ecution of the procedure and assessment of the results.
Keywords Paravalvular leak · Prosthetic heart valve ·
Heart failure · Haemolytic anaemia · Amplatzer Vascular
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Introduction
Paravalvular leak (PVL) is a serious complication after sur-
gical valve replacement or after transcatheter aortic valve
replacement (TAVR) [1, 2]. The incidence of PVLs after
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surgical valve replacement varies in different studies, rang-
ing from 2–10% in the aortic position and from 7–17% in
the mitral position [1, 3, 4]. Significant (moderate or se-
vere) paravalvular regurgitation has been reported in up to
one-quarter of patients following TAVR [5].
Although most PVLs are small, remain asymptomatic
and follow a benign clinical course, larger PVLs with se-
rious clinical consequences, such as heart failure, severe
haemolytic anaemia or endocarditis, occur in 1–5% of pa-
tients who have undergone surgical valve replacement, with
most occurring in association with prosthetic mitral valves
[3, 4, 6, 7].
For years, surgical re-intervention has been considered
the treatment of choice for symptomatic patients with PVLs.
It was shown that the overall mortality was lower in the sur-
gical re-intervention group compared with the group treated
conservatively [4]. However, the operative mortality of sur-
gical treatment of PVL is still high. Long-term outcomes
remain suboptimal in these challenging patients, especially
in the presence of multiple previous surgical re-interven-
tions and associated co-pathologies [8]. Transcatheter PVL
(TPVL) closure has emerged as a safe, effective and less
invasive alternative to surgical re-intervention [9–12] with
durable symptom relief in selected patients [10].
In this review, we discuss the clinical implications and
diagnosis of PVLs, technical considerations for TPVL, ex-
ecution of the procedure and assessment of results.
Diagnosis of paravalvular leak
In some cases, PVL diagnosis can be challenging. Often the
first signs of suspicion are the presence of an abnormal mur-
mur in the physical examination and the evidence of sig-
nificant haemolytic anaemia in blood tests. Blood cultures
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Fig. 1 Mechanical prosthetic valve with four PVLs (a–d show different positions of leaks in 2D and colour echocardiography). To locate and
assess different leaks on 2D echo needs a careful search. Instead, colour 3D-TEE makes this an easier task (e), taking into consideration the lower
temporal and spatial resolution. It is necessary to refer PVL in relation to anatomic reference points (f). Taking the surgeon’s view from left
atrium, leaks would be referred to in hours, as a clock, taking mitro-aortic curtain as 12 h and/or by position segments. LAA left atrial appendage,
IAS interatrial septum
Fig. 2 3D-TEE during TPVL closure over mechanical prosthetic mitral valve with the leak partially closed with three devices and a residual
defect at 10–11 h (a). Cropping 3D-volume (b) is possible to visualise the leak tunnel (#). PVL assessment using multiplanar reformatting over
3D-colour (c). After transseptal puncture, guide and sheath are moved to left atrium (d) and crossed through PVL (e and f, same cropping as b).
Device deployment should be monitored to detect any disturbance (g) and reduction in regurgitation (h) prior to device release (i and j). Fusion
imaging could be useful, for example, during transseptal puncture (k) or crossing the PVL with the guide wire (l)
to eliminate endocarditis should be considered. In cases of
suspected PVL, patient evaluation must be followed by an
echocardiography study to confirm the diagnosis. Two-di-
mensional (2D) transoesophageal echocardiography (TEE)
is very sensitive in accurately identifying the presence of
PVL [13]; however, in many cases, assessing the number,
shape and location of the defects with 2D-TEE is practi-
cally impossible [14]. Three-dimensional (3D)-TEE allows
better definition of the PVLs, making this technique the
gold standard for PVL evaluation (Fig. 1). 3D-TEE is es-
pecially useful for mitral PVLs, being almost mandatory
for a correct diagnosis [15–17]. It is recommended that mi-
tral PVL location be reported in a clockwise format from
a surgeon’s perspective or ‘surgical view’ (Fig. 1; [15, 16,
18]). Also, the aortic PVL location should be reported in
a clockwise format [9]. TEE is crucial during the TPVL
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Fig. 3 Technical approaches
to TPVL closure. a Mitral
PVL closure using an ante-
grade transseptal approach.
b Mitral PVL closure using
a retrograde approach. c Aortic
PVL closure using a retrograde
approach. d Mitral PVL clo-
sure using a deflectable sheath.
APV aortic prosthetic valve,
MPV mitral prosthetic valve,
Ao Aorta, AL Amplatzer left,
LA left atrium, LV left ventri-




KEY MESSAGE  Transcatheter paravalvular leak closure is a safe, effective and less invasive alternative to 
surgical re-intervention.                               
closure procedure, while 3D-TEE plays an essential role
in the selection of the closure device, for guiding the pro-
cedure, and assessment of the results (Fig. 2; [15, 16]).
Furthermore, fusion imaging techniques provide a valuable
extra help during the procedure, i. e. EchoNavigator auto-
matically fuses live 3D-TEE and live X-ray in real time, so
it can intuitively guide the procedure in the 3D space.
Due to the complexity of some defects, other image
modalities such as computed tomography (CT) and cardiac
magnetic resonance (CMR) could be very useful [16, 19].
Recently introduced tools such as the 3D-Heart Navigator,
which combine 3D-CT images with an overlay of the live
X-ray fluoroscopy information, can also assist during the
procedure.
Transcatheter techniques for TPVL closure
Crossing the PVL
Mitral TPVL closure: In the antegrade approach (Fig. 3),
once a successful transseptal puncture is made, a diagnos-
tic catheter (e. g., Judkins right) is advanced into the left
atrium. After that, a hydrophilic guidewire (e. g., Terumo
guidewire, Terumo Medical Corporation) is often used to
cross the mitral PVL and in most cases an arteriovenous
loop is established in the aorta, alternatively an extra-sup-
port wire can be placed in the left ventricle. Finally, a deliv-
ery sheath is advanced from the venous access over the loop
or extra-support wire and the device is deployed. Before re-
leasing, the disc movement in mechanical valves should be
confirmed. It can be very helpful to use a safety guidewire
to avoid having to re-cross the PVL. Sometimes (e. g. in
septal PVL or if the angle between the transseptal puncture
and the defect is unfavourable) it can also be very helpful
to use a deflectable catheter (e. g., Agilis, St Jude Medical),
(Fig. 3; [11]).
In the retrograde approach, a hydrophilic guidewire
(e. g., Terumo guidewire, Terumo Medical Corporation)
over a catheter (e. g., Judkins right) is often used to cross
the PVL from the left ventricle to the left atrium. After
crossing, an arteriovenous wire loop is often created in
the left atrium; therefore, a transseptal puncture is needed.
Finally, the delivery sheath is advanced from the venous
access and the device is deployed (Fig. 3).
Transapical access can be a good alternative for mitral
PVL closure (especially for posterior or septal defects or
patients with mitro-aortic mechanical valves) [9]. The main
advantages of this access are the often less difficult wiring
of the PVL and less resistance to cross the PVL.
Aortic PVL closure: The retrograde approach is used for
closure of most aortic PVLs (Fig. 3). The defect is usu-
ally crossed using a hydrophilic guidewire over a catheter
(e. g. Amplatzer Left-1). After crossing, this guidewire is
exchanged for a stiffer wire (e. g., Amplatz Super-stiffTM,
Boston Scientific). Finally, the delivery sheath is advanced
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(every 1 mm up to 20 mm,
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7 mm 8 mm 5–9
ADO 5–16 mm distal end and
4–14 mm proximal
5–8 mm 4 mm (ADO 5/4–8/6)
6 mm (ADO 10/8–16/14)
5–7
AVP II 3–22 mm (every 2 mm) 6 mm – 4–7
AVP III Long axis: 4–14 mm
Short axis: 2–5 mm
2–5 mm 2 mm 4–7
AVP IV 4–8 mm 10–13.5 mm – 4–5
Occlutech devices
Length of the distal disc Length of the proxi-
mal disc
Length × Width Size (Fr)
































































































and the device is deployed. In some cases an arterio-arterial
loop can be established for added support. The technique
for PVL closure after TAVR is similar to the technique for
aortic PVLs after surgical valve replacement [20].
Choosing the sheath
There are different sheaths that can be used for delivering
the device. The size of the leak dictates the device, which
dictates the sheath/guide used for delivery (Table 1). In
most of the cases the Amplatzer TorqVue (St Jude Medical,
St. Paul, MN, USA) sheaths are used. If there is diffi-
culty in crossing the leak, other options such as the Terumo
Destination Guiding Sheath (Terumo, Japan) or the Sheath-
less Eucath (Ashahi Intec, Japan) should be considered as
they provide a larger lumen with smaller outer diameter.
It should be taken into account that the largest Occlutech
Paravalvular Leak Devices (PLD, Occlutech, Helsingborg,
Sweden) need a 10 F sheath. In certain cases, where TPVL
closure cannot be completely achieved with a single de-
vice, multiple devices can be deployed using simultaneous
sheaths or sequentially using different techniques [21].
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Fig. 4 PVL closure devices. a Amplatzer Muscular VSD Occluder. b Amplatzer Duct Occluder. c Amplatzer Vascular Plug III. d Occlutech
PLD (square-shaped design). e Amplatzer Septal Occluder. f Amplatzer Vascular Plug II. g Amplatzer Vascular Plug IV. h Occlutech PLD
(rectangular-shaped design)
Choosing the device
Most of the devices used today have not been designed,
tested, or approved for PVL closure and they are used
‘off-label’ for this purpose (Fig. 4). PVLs are variable in
size and shape with many being crescentic and serpiginous,
rather than cylindrical, which makes it extremely difficult
for one device to fit in all PVLs. Amplatzer devices (St.
Jude Medical, St. Paul, MN, USA) are currently the most
used for TPVL closure [9, 11, 22–24]. The Amplatzer Vas-
cular Plug (AVP) II is widely used in the USA while in Eu-
rope the most frequently used device is the AVP III. At this
time, the only device specifically approved to TPVL closure
by the European Commission is the Occlutech PLD [25].
For a small cylindrical PVL, we will often use an AVP II
or PDA occluder. For an oval PVL, an AVP III occluder is
preferred. For a small PVL with significant angulation and
a small neck (typically after TAVR), an AVP IV occluder
can be considered. Sizing of these devices usually comes
from 2D- and 3D-TEE measurements. Angiography can
also be useful for aortic PVL. The PLD rectangular-shaped
device is also recommended to cover crescent-shaped de-
fects while avoiding interference with the valve.
Outcomes and complications of PVL closure
procedures
The safety and feasibility of TPVL closure has been con-
firmed in several registries and a meta-analysis [9, 10, 12,
23, 26]. Reported technical and clinical success ranged
from 77–86% and 67–77% respectively (Table 2; [9, 10, 12,
23, 26, 27]). Also, successful TPVL closure has been as-
sociated with a lower cardiac mortality rate compared with
failed closure (260 patients; OR 0.08; 95% CI 0.01–0.90),
a positive tendency toward lower all-cause mortality (311
patients; OR 0.52; 95% CI, 0.09–1.74) and a superior func-
tional class improvement or improved haemolytic anaemia
compared with failed TPVL closure (267 patients; OR 9.95;
95% CI, 2.10–66.73). Complication rates are low at expe-
rienced centres (Table 3; [9, 10, 22, 23, 28, 29]). It has re-
cently been shown in a single-centre non-randomised study
that percutaneous PVL closure results compare favourably
with surgical treatment [30]. Furthermore, in 308 PVL
closure procedures attempted in 259 patients in 20 centres
Calvert et al. [29] reported a technical success rate of 91%,
PVL improved post-procedure (p < 0.001) and was none
(33.3%), mild (41.4%), moderate (18.6%) or severe (6.7%)
at last follow-up. The mean New York Heart Association
class improved from 2.7 ± 0.8 pre-procedure to 1.6 ± 0.8
(p < 0.001) after a median follow-up of 110 (7–452) days.
On the other hand, experience with TPVL closure after
TAVR is still limited, but it could be a reasonable strat-
egy in selected patients [2]. TPVL closure after TAVR
is associated with high success rates and with an improved
functional status [2]. The most used devices are the AVP II,
III and IV [2].
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Table 2 Summary of main PVL closure studies
Hein [28] Cortés [26] Ruiz [9] Sorajja [11] Noble [27] Cruz [23] Sánchez [22] Calvert [29]
Patients, n 21 27 43 126 56 33 20 259
Mean age, years 65 63 69 67 65 71 68 67
























































































































































95 62 86 91 75 94 85 91
Procedural
success, %




to 1.6 ± 0.8
Mean follow-up,
months
13.5 3 42 11 (median) 30 (median) 3 12 (median) 3.7 (median)
PVL paravalvular leak, CHF chronic heart failure, AVP Amplatzer vascular plug, ADO Amplatzer duct occluder, mVSD Amplatzer muscular ven-
tricular septal defect occluder, ASO Amplatzer septal occluder, OPLD Occlutech® Paravalvular Leak Device, NYHA New York Heart Association
Table 3 Main complications associated with PVL closure
Complication Percentage
Device embolisation 4% [9]
Cardiac perforation 4%a [9], 0% [23], 0% [11]
Death 2% [9], 1,7% [11]
Vascular complications 2% [9], 0,9% [11]




Intracranial haemorrhage 0.9% [11]
Sepsis 0.9% [11]
aTransapical access
Medical therapy and follow-up
For patients under anticoagulation therapy this should be
continued after the procedure. Dual antiplatelet therapy for
at least 3 months is recommended in non-anticoagulated pa-
tients (i. e. biological prostheses). Post-procedural imaging
with TEE to assess device position and residual regurgita-
tion is recommended. The timing of a follow-up TEE varies
between institutions but we recommend an initial early TEE
3 months after procedure.
Conclusions and future directions
TPVL closure in symptomatic patients with severe PVL
is a less invasive option than surgical re-intervention, with
lower procedural morbidity and mortality. However, sur-
gical re-intervention is still a valuable option for large de-
fects or cases that cannot be treated percutaneously. To
continue to improve procedural success and outcomes, new
advancements in device designs are necessary. The ideal
PVL closure device should meet the following criteria:
122 Neth Heart J (2017) 25:116–124
(a) should conform to the often ‘irregular’ defects, (b) have
low-profile deliverability, (c) be repositionable and retriev-
able, (d) avoid interference with prosthetic valve leaflets,
(e) accomplish complete closure of the defect, (f) have
a low risk of embolisation or dislodgement and (g) should
not be thrombogenic. In the same way recently introduced
imaging tools such as the 3D-Heart Navigator or the Echo
Navigator will improve the results of this complex inter-
vention.
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